Article info

Download PDFPDF
Original article
Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases

Authors

  • Aura D Urribarri Division of Gene Therapy and Hepatology, CIMA of the University of Navarra, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Patricia Munoz-Garrido Department of Liver and Gastrointestinal Diseases, Biodonostia Research Institute—Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastián, Spain PubMed articlesGoogle scholar articles
  • María J Perugorria Department of Liver and Gastrointestinal Diseases, Biodonostia Research Institute—Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastián, Spain National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, Instituto de Salud Carlos III), Spain IKERBASQUE, Basque Foundation for Science, Bilbao, Spain PubMed articlesGoogle scholar articles
  • Oihane Erice Department of Liver and Gastrointestinal Diseases, Biodonostia Research Institute—Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastián, Spain PubMed articlesGoogle scholar articles
  • Maite Merino-Azpitarte Department of Liver and Gastrointestinal Diseases, Biodonostia Research Institute—Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastián, Spain PubMed articlesGoogle scholar articles
  • Ander Arbelaiz Department of Liver and Gastrointestinal Diseases, Biodonostia Research Institute—Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastián, Spain PubMed articlesGoogle scholar articles
  • Elisa Lozano Department of Physiology and Pharmacology, Experimental Hepatology and Drug Targeting (HEVEFARM), Biomedical Research Institute of Salamanca (IBSAL), University of Salamanca, Salamanca, Spain PubMed articlesGoogle scholar articles
  • Elizabeth Hijona Department of Liver and Gastrointestinal Diseases, Biodonostia Research Institute—Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastián, Spain National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, Instituto de Salud Carlos III), Spain PubMed articlesGoogle scholar articles
  • Raúl Jiménez-Agüero Department of Liver and Gastrointestinal Diseases, Biodonostia Research Institute—Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastián, Spain PubMed articlesGoogle scholar articles
  • Maite G Fernandez-Barrena Division of Gene Therapy and Hepatology, CIMA of the University of Navarra, Pamplona, Spain National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, Instituto de Salud Carlos III), Spain PubMed articlesGoogle scholar articles
  • Juan P Jimeno Division of Gene Therapy and Hepatology, CIMA of the University of Navarra, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Marco Marzioni Department of Gastroenterology, ‘Università Politecnica delle Marche’, Ancona, Italy PubMed articlesGoogle scholar articles
  • Jose J G Marin National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, Instituto de Salud Carlos III), Spain Department of Physiology and Pharmacology, Experimental Hepatology and Drug Targeting (HEVEFARM), Biomedical Research Institute of Salamanca (IBSAL), University of Salamanca, Salamanca, Spain PubMed articlesGoogle scholar articles
  • Tatyana V Masyuk Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA PubMed articlesGoogle scholar articles
  • Nicholas F LaRusso Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA PubMed articlesGoogle scholar articles
  • Jesús Prieto Division of Gene Therapy and Hepatology, CIMA of the University of Navarra, Pamplona, Spain National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, Instituto de Salud Carlos III), Spain PubMed articlesGoogle scholar articles
  • Luis Bujanda Department of Liver and Gastrointestinal Diseases, Biodonostia Research Institute—Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastián, Spain National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, Instituto de Salud Carlos III), Spain PubMed articlesGoogle scholar articles
  • Jesús M Banales Division of Gene Therapy and Hepatology, CIMA of the University of Navarra, Pamplona, Spain Department of Liver and Gastrointestinal Diseases, Biodonostia Research Institute—Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastián, Spain National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, Instituto de Salud Carlos III), Spain IKERBASQUE, Basque Foundation for Science, Bilbao, Spain Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Jesús M Banales, Department of Liver and Gastrointestinal Diseases, Biodonostia Research Institute-Donostia University Hospital, Paseo del Dr Begiristain sn, San Sebastián E-20014, Spain; jesus.banales{at}biodonostia.org
View Full Text

Citation

Urribarri AD, Munoz-Garrido P, Perugorria MJ, et al
Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases

Publication history

  • Received May 15, 2013
  • Revised December 20, 2013
  • Accepted December 21, 2013
  • First published January 16, 2014.
Online issue publication 
September 02, 2014

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.